Please login to the form below
salmeterol
This page shows the latest salmeterol news and features for those working in and with pharma, biotech and healthcare.
GSK seeks EU approval for Trelegy in adult asthma patients
GSK’s respiratory business has been hit with the loss of patent protection for its COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol) – Trelegy is GSK’s answer to the increased competition
Latest news
-
GSK considers more divestments to help R&D push
She said it was encouraging that in the year that generic competition really bit hard into sales of GSK’s longstanding respiratory blockbuster Advair/Seretide (fluticasone propionate/salmeterol), the group was
-
Boehringer posts solid first half as business revamp beds in
Meanwhile, the COPD category has been affected by the arrival of generics of big-selling brands like GlaxoSmithKline’s Advair (salmeterol/fluticasone propionate).
-
GSK’s Advair Diskus faces first generic in US
Teva won approval for its AirDuo product last year in the US, providing the same active ingredients as Advair but with a lower dose of salmeterol which means it is not
-
Is GSK planning to exit the respiratory business?
Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)
-
AZ rival to GSK’s COPD drug Anoro fails head-to-head test
Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent
More from news
Approximately 1 fully matching, plus 88 partially matching documents found.
Latest from PMHub
-
Raising Awareness: It’s World COPD Day today!
Common combinations include fluticasone proprionate/salmeterol and budesonide/formoterol, which are taken twice-daily, and fluticasone furoate/vilanterol, which is taken once-daily (5).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
